Kura Oncology and Kyowa Kirin submitted data from the KOMET-001 trial, which the agency will review and decide whether to approve the drug by Nov. 30.

Various factors contribute to disparities in 30-day readmission rates following allogeneic hematopoietic stem cell transplantation (allo-HCT) among patients with acute myeloid leukemia (AML), ...

DelveInsight’s Natural Killer (NK)-Cell Lymphoma Pipeline report depicts a robust space with 100+ active players working to develop 140+ pipeline therapies for Natural Killer (NK)-Cell Lymphoma ...

InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today the approval of the Investigational New ...

Outcomes of Children With BCR-ABL1–Like Acute Lymphoblastic Leukemia Treated With Risk-Directed Therapy Based on the Levels of Minimal Residual Disease Concurrently performed, our trial's primary ...

So, this is very encouraging news." Burke is director of the Leukemia Lymphoma Program at the Children's Hospital of Wisconsin in Milwaukee. There's more on acute myeloid leukemia at the U.S. National ...

A highly sensitive bone marrow test could double survival rates for some groups of younger adults with acute myeloid leukemia (AML) by helping doctors identify if they might relapse up to three ...

Recent progress in the molecular genetics of acute myeloid leukemia (AML) has shown this disease to be more heterogeneous than previously realized. Recurrent cytogenetic and mutational changes in ...

Taurine, a common ingredient in energy drinks, has been linked to leukemia cell growth. New research suggests targeting taurine uptake for leukemia treatment strategies.